Steven R. Pacelli - Jun 23, 2022 Form 4 Insider Report for DEXCOM INC (DXCM)

Role: EVP Managing Director Dexcom V
Signature: By: Jereme Sylvain For: Steven R Pacelli
Stock symbol: DXCM
Transactions as of: Jun 23, 2022
Transactions value $: -$72,550
Form type: 4
Date filed: 6/27/2022, 04:46 PM
Previous filing: May 25, 2022
Next filing: Jul 25, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DXCM	Common Stock	Sale	-$72.6K	-1K	-0.71%	$72.55	140K	Jun 23, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2	Adjusted to reflect Dexcom's 4-for-1 stock split, effective on June 10, 2022. Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

Content

On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

Adjusted to reflect Dexcom's 4-for-1 stock split, effective on June 10, 2022. Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023.